key: cord-0896673-8x8xsnkz
authors: Wang, Xiaofei; Hu, Ao; Chen, Xiangyu; Zhang, Yixin; Yu, Fei; Yue, Shuai; Li, Arong; Zhang, Junsong; Pan, Zhiwei; Yang, Yang; Lin, Yao; Gao, Leiqiong; Zhou, Jing; Zhao, Jing; Li, Fang; Shi, Yaling; Huang, Feng; Yang, Xiaofan; Peng, Yi; Tu, Luoyang; Zhang, Huan; Zheng, Huanying; He, Jun; Zhang, Hui; Xu, Lifan; Huang, QizhAo; Zhu, Yongqun; Deng, Kai; Ye, Lilin
title: A potent human monoclonal antibody with pan-neutralizing activities directly dislocates S trimer of SARS-CoV-2 through binding both up and down forms of RBD
date: 2022-01-13
journal: bioRxiv
DOI: 10.1101/2021.11.29.470356
sha: fada983bcd3227bf0cf7d3ffa0b24de1df1c96e4
doc_id: 896673
cord_uid: 8x8xsnkz

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel corona virus disease (COVID-19). The neutralizing monoclonal antibodies (mAbs) targeting the receptor binding domain (RBD) of SARS-CoV-2 are among the most promising strategies to prevent and treat COVID-19. However, SARS-CoV-2 variants of concern (VOCs) profoundly reduced the efficacies of most of mAbs and vaccines approved for clinical use. Herein, we demonstrated mAb 35B5 efficiently neutralizes both wild-type (WT) SARS-CoV-2 and VOCs, including B.1.617.2 (delta) variant, in vitro and in vivo. Cryo-electron microscopy (cryo-EM) revealed that 35B5 neutralizes SARS-CoV-2 by targeting a unique epitope that avoids the prevailing mutation sites on RBD identified in circulating VOCs, providing the molecular basis for its pan-neutralizing efficacy. The 35B5-binding epitope could also be exploited for the rational design of a universal SARS-CoV-2 vaccine.

subtly avoids the prevailing mutation sites, which provides the molecular basis for the 246 potent pan-neutralizing efficacy of 35B5 to the SARS-CoV-2 VOCs. 247 248 Neutralization mechanism of mAb 35B5 249

To investigate the neutralization mechanism of 35B5, we analyzed the "down" RBD 250 domain in the State 1 35B5 Fab-S-6P complex. In the density map of the State 1 251 complex, there were some residual densities closed to the "down" RBD domain. We 252 further carried out local refinements on the "down" RBD. The local refinements 253 generated a 4.8-Å density map and revealed that there is a 35B5 Fab contacting the 254 edge of the epitope on the "down" RBD. The low resolution of the local refinement 255 map suggests that the interaction between the 35B5 Fab and the "down" RBD is 256 highly dynamic . Structural modeling after the local 257 refinements revealed that, in contrast to the neutralizing mAbs BD-368 21, 22 and 258 C002 23 recognizing the epitopes that are fully exposed in both "down" and "up" 259 RBDs, 35B5 Fab utilizes the CDRH regions to interact with the residues E340, T345, 260 R346, F347, R346, K444, Y449 and N450 at the exposed edge of the epitope on the 261 "down" RBD, indicating that this RBD domain is being initially recognized by 35B5 262 ( Fig. 4d and Supplementary Fig. 4e and Supplementary Fig. 7a, c) . Structural 263 superimposition of the 35B5 Fab-"up" RBD model with the "down" RBD in the 35B5 264

Fab-S-6P complex of State 1 or those in the Fab-free spike trimers 21, 28 reveals that the 265 β-sheet and the linking loop of FRH1 of 35B5 Fab have severe structural clashes with 266 14 the adjacent NTD domain of the spike protein (Fig. 4e) , suggesting that upon the 267 high-affinity binding of 35B5 Fab onto the "down" RBD, the spatial collisions 268 between 35B5 Fab and the NTD domain potentially exert repulsion force onto the 269 NTD domain to induce the conformational conversion of RBD from "down" to "up" 270 conformation. Further outward movement of the "up" RBDs generated the "releasing" 271 conformations in the State 3 35B5 Fab-S-6P complex. Thus, the 35B5 Fab-S-6P 272 complex structures in these three states suggest that neutralization of SARS-CoV-2 by 273 35B5 is likely carried out in four sequential steps ( Fig. 4g ): 35B5 firstly binds to the 274 exposed edge of the epitope to recognizes the "down" RBDs of the spike protein; 275 subsequently, binding of 35B5 imposes structural clashes on the NTD domain to drive 276 the conformational changes of RBDs from "down" to "up"; next, the unstable "up" 277 conformations of the RBD domains destabilizes the structure of the spike trimer and 278 induces the outward movement and releasing of RBDs; finally, the released RBD 279 domains cause the dissociation of the spike trimer. 280

The SARS-CoV-2 VOCs contains the most prevalent mutation D614G in the 281 spike protein, which enhances infectivity by inducing the wedge of a disordered loop 282 between the SD1/CTD1 and NTD domains within a protomer to prevent premature 283 dissociation of the G614 trimer 29 . The residue D614 is not located in the epitope of 284 35B5 (Fig. 3b) Fig. 6a-f ). The binding surface of 32C7 Fab on RBD 299 overlaps with the epitopes of the class 3 antibodies ( Supplementary Fig. 6c) , 300 suggesting that 32C7 belongs to the classic class 3 family of neutralizing antibodies. 301

The 32C7 Fab-RBD interface only covers a buried area of approximately 935 Å 2 , 302 which is much less than that of 35B5 Fab ( Fig. 3c and Supplementary Fig. 6g and 303 Supplementary Fig. 7b, d) . The smaller epitope surface on RBD determined the 304 weaker neutralization efficacy of 32C7 as compared to that of 35B5 (Fig. 1) In this study, we demonstrate 35B5 as a ultrapotent and pan-neutralizing human 316 monoclonal antibody against currently circulating SARS-CoV-2 provided by 317 experimental evidence in vitro and in vivo as well as structural analysis. By contrast, 318 many mAbs such as casirivimab (REGN10933), bamlanivimab (LY-CoV555), 319 etesevimab (LY-CoV016), regdanvimab (CT-P59), ABBV-2B04 (2B04) and 32C7 in 320 the study partially or entirely lose the neutralizing activity against B.1.351 and 321 B.1.617.2 2, 10, 30, 31 . The mechanisms underlying the picomolar broad neutralization by 322 35B5 at least involve three aspects: 1) broad interface and extensive interactions 323 between 35B5 and RBD endow 35B5 as a potent cross-epitope mAb; 2) proactive 324 dissociation of the spike trimer by structural clashes between 35B5 Fab FRH1 and 325 spike NTD domain; 3) no direct contacts between 35B5 Fab and prevailing mutations 326 of SARS-CoV-2 VOCs. 327

Previous works indicated that the ACE-binding surface is partially exposed on the 328 "down" RBDs in the tight-or loose-closed spike trimer 21, 28 . The epitopes of some 329 17 neutralizing mAbs are also partially exposed on the "down" RBDs 23, 32, 33, 34, 35 . The 330 35B5 Fab-S-6P complex structures in the three states we determined provide for the 331 first time the direct structural evidence for the possibility that the ACE2 or mAbs can 332 approach the partially exposed surface or epitope residues for initial recognition and 333 fulfil the conformational transformation of RBD. In previously identified 334 RBD-targeted mAbs, almost all class 1 mAbs interact extensively with the residues 335 K417 and N501. Most class 2 and class 3 mAbs contact E484, and most class 3 mAbs 336 interact with L452 3 . 35B5 does not directly bind to these prevailing mutant sites. In 337 contrast to the Class 3 mAb S309 26 and the Class 4 mAb CR3022 36 , which target the 338 residues conserved in the spike proteins of SARS-CoV, SARS-CoV-2 and 339 MERS-CoV and therefore have cross-species neutralizing activities, 35B5 is a 340 SARS-CoV-2 specific antibody with super potent pan-neutralizing activities to 341 SARS-CoV-2 VOCs. 342

Protective vaccines are considered as keys to terminate the COVID-19 pandemic. 343

However, accumulating evidence suggests that SARS-CoV-2 VOCs compromise 344 neutralization by antibody responses induced by multiple vaccines 12, 13, 14, 15, 37, 38, 39 , 345 including mRNA vaccines (BNT162b2 and mRNA-1273), adenovirus-based vaccines 346 (AZD1222 and JNJ-78436735), a nanoparticle-based vaccine (NVX-CoV2373) and 347 an inactivated protein vaccine (Coronavac), primarily due to RBD mutations. Thus, 348 vaccines aimed at eliciting broadly neutralizing mAbs against SARS-CoV-2 VOCs are 349 urgently needed. In the scenario of coping with diverse HIV-1 variants, an 350 18 experimental pan-HIV-1 vaccine was designed based on the structurally defined 351 epitope of a HIV-1 neutralizing mAb N123-VRC34.01, which targets a linear peptide 352 of fusion peptide that is across-clade conserved 40, 41 . In our study, cryo-EM structure 353 of neutralizing 35B5 to the SARS-CoV-2 spike revealed an epitope that is composed 354 of 30 residues and conserved among all the currently known SARS-CoV-2 VOCs. 355 Importantly, mAb 35B5 was cloned from SARS-CoV-2 RBD-specific B cells 356 obtained from individuals during their early convalescence, which might endow mAb 357 35B5 with limited somatic hypermutation (SHM). In contrast, a broad neutralizing 358 mAb, ADG-2, was engineered by in vitro affinity optimization 42 and the extensive 359 SHM makes ADG-2 epitope challenging as a target for SARS-CoV-2 vaccines. Thus, 360

we propose that the 35B5 epitope might be a valuable target for the rational design of 361 a universal SARS-CoV-2 vaccine, which is presumably essential for the ultimate 362 termination of COVID-19 pandemic in the future. images were then imported into cryoSPARC 50 for the following image processing, 584 including CTF estimation, particle picking and extraction, 2D classification, ab initio 585 3D reconstruction, heterogeneous 3D refinement and non-uniform homogeneous 586 refinement. For the S-6P-35B5 Fab complex, 8 representative particle templates were 587 generated in 2D classification of 65,242 particles auto-picked by the blob picker from 588 the first 1000 micrographs. Using these templates, 1,178,527 particles were extracted 589 with a box size of 330×330 and classified into 150 classes in 2D classification. 590

Among them, 43 classes that included 818,470 particles were selected for ab initio 3D 591 reconstruction and heterogeneous refinement. Finally, 392,378 particles reconstructed 592 an apparent architecture of the S-6p-35B5 Fab complex and were subjected to two 593 more rounds of ab initio 3D reconstruction and heterogeneous refinement before 594 non-uniform refinement. Then the particles were subjected to global and local CTF 595 refinement for final non-uniform refinement, and generated three abundant 596 27 populations of the S-6P-35B5 Fab complex and structures. Local refinements of the 597 RBD-35B5 Fab region were performed to improve the interface density in 598 cryoSPARC. Sharpened maps were generated and validated for model building and 599 refinement. Reported resolutions are based on the gold-standard Fourier shell 600 correlation 51, 52 of 0.143 criterion. 601

For the S-6P-32C7 Fab complex, 4 representative particle templates were 602 generated in 2D classification of 122,851 particles auto-picked by the blob picker 603 from the first 1000 micrographs. Based on these templates, 744,865 particles were 604 extracted with a box size of 380×380 and classified into 150 2D classes. Among them, 605 28 classes including 338,454 particles were selected for ab initio 3D reconstruction 606 and heterogeneous refinement. 125,858 particles that reconstructed an apparent 607 architecture of the S-6P-32C7 Fab complex were subjected to two more rounds of ab 608 initio 3D reconstruction and heterogeneous refinement before non-uniform refinement. 609

Finally, the S-6P-32C7 Fab complex structure that only includes a bound 32C7 Fab 610 was reconstructed from 119,062 particles. Local refinement of the RBD-32C7 Fab 611 region was also performed. 

World Health Organization. Weekly epidemiological update on COVID-19 -647

Tackling COVID-19 with 652 neutralizing monoclonal antibodies

Structural and functional ramifications of antigenic drift in 655 recent SARS-CoV-2 variants

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G 658 on Transmissibility and Pathogenicity

Estimated transmissibility and impact of SARS-CoV-2 661

Detection of a SARS-CoV-2 variant of concern in South 664

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage 667 30

Convergent evolution of SARS-CoV-2 spike mutations

L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

bioRxiv : the preprint server for biology

Resistance of SARS-CoV-2 variants to neutralization by 674 monoclonal and serum-derived polyclonal antibodies

SARS-CoV-2 variants B.1.351 and P.1 escape from 678 neutralizing antibodies

SARS-CoV-2 variant B.1.617 is resistant to Bamlanivimab 681 and evades antibodies induced by infection and vaccination. bioRxiv : the 682 preprint server for biology

Multiple SARS-CoV-2 variants escape 685 neutralization by vaccine-induced humoral immunity

Infection-and vaccine-induced antibody binding and 689 neutralization of the B.1.351 SARS-CoV-2 variant

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

mRNA vaccine-elicited antibodies to SARS-CoV-2 and 696 circulating variants

Disease severity dictates SARS-CoV-2-specific neutralizing 699 antibody responses in COVID-19

Maturation and persistence of the anti-SARS-CoV-2 memory B 703 cell response

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. 706

A Mouse Model of SARS-CoV-2 Infection and Pathogenesis

Cryo-EM structure of the 2019-nCoV spike in the prefusion 712 conformation

Structure-based design of prefusion-stabilized SARS-CoV-2 715 spikes

Structurally Resolved SARS-CoV-2 Antibody Shows High 718

Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing 719

SARS-CoV-2 neutralizing antibody structures inform 722 therapeutic strategies

Receptor binding and priming of the spike protein of 725

SARS-CoV-2 for membrane fusion

Structure of the SARS-CoV-2 spike receptor-binding domain 728 bound to the ACE2 receptor

Cross-neutralization of SARS-CoV-2 by a human monoclonal 731 SARS-CoV antibody

The Emergence of SARS-CoV-2 Variant Lambda

South America. medRxiv : the preprint server for health sciences

Free fatty acid binding pocket in the locked structure of 737

SARS-CoV-2 spike protein. Science

Structural impact on SARS-CoV-2 spike protein by D614G 740 substitution

Antibody evasion by the P.1 strain of SARS-CoV-2

Increased resistance of SARS-CoV-2 variant P.1 to antibody 746 neutralization

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV 749 by a potent therapeutic antibody

Ultrapotent human antibodies protect against 753

SARS-CoV-2 challenge via multiple mechanisms

Neutralization of SARS-CoV-2 by Destruction of the Prefusion 757

Structural insight into SARS-CoV-2 neutralizing antibodies 760 and modulation of syncytia

A highly conserved cryptic epitope in the receptor binding 763 domains of SARS-CoV-2 and SARS-CoV

South Africa Suspends Use of AstraZeneca's COVID-19 Vaccine 767 after It Fails to Clearly Stop Virus Variant

Susceptibility of Circulating SARS-CoV-2 Variants to 773

New Data Shed Light on Efficacy of J&J's

Single-Dose Covid Vaccine

Epitope-based vaccine design yields fusion peptide-directed 781 antibodies that neutralize diverse strains of HIV-1

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing 785 antibody

Broad and potent activity against SARS-like viruses by 788 an engineered human monoclonal antibody

Human monoclonal antibodies block the binding of

SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

Rapid generation of fully human monoclonal antibodies 796 specific to a vaccinating antigen

Surface plasmon resonance-based methodology for 799 anti-adalimumab antibody identification and kinetic characterization

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Pathogenesis, Vaccination, and Treatment. Cell 182, 734-743.e735 (2020) . 807 808 48.Lei J, Frank J. Automated acquisition of cryo-electron micrographs for single 809 particle reconstruction on an FEI Tecnai electron microscope. J Struct Biol 810 150, 69-80 (2005) . Scheres SH, Chen S. Prevention of overfitting in cryo-EM structure 824 determination. Nat Methods 9, 853-854 (2012 mechanism of 35B5 against SARS-CoV-2. The "down" and "up" RBDs in the 950 tight-closed or loose-closed S trimers are colored in blue and yellow, respectively. 951The conformation changes and transmission of RBDs from the "down" to "up", 952 finally to "releasing" states are shown as red arrows. SARS-CoV-2 variants of concern or interest. b-g The residues E484 (b) and L452 (d) 958are not involved in the interactions of RBD with 35B5 Fab. E484 is more than 4.2 Å 959 away from 35B5 R84, which forms cation-π interaction with RBD F490. The E484K 960 mutation in RBD does not interact with 35B5 R84 through molecular modelling (c). 961The L452Q modelling suggests none interactions formed at this site with 35B5 (f). In 962 structural modeling, the L452R mutation (e) and F490S mutation (